Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2019 3
2021 1
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Ozelo MC, et al. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708. N Engl J Med. 2022. PMID: 35294811 Clinical Trial.
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DV, Symington E, Leavitt AD, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele KM, Reddy DB, Henshaw J, Robinson TM, Wong WY, Pipe SW; GENEr8-1 Trial Group. Mahlangu J, et al. N Engl J Med. 2023 Feb 23;388(8):694-705. doi: 10.1056/NEJMoa2211075. N Engl J Med. 2023. PMID: 36812433 Clinical Trial.
Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.
Camelo RM, Dias MM, Caram-Deelder C, Gouw S, de Magalhães LP, Zuccherato LW, Jardim LL, de Oliveira AG, de Albuquerque Ribeiro R, Franco VKB, do Rosário Ferraz Roberti M, de Araújo Callado FMR, Etto LY, de Cerqueira MAF, Cerqueira MH, Lorenzato CS, de Souza IS, Serafim ÉSS, Garcia AA, Anegawa TH, Neves DCF, Tan DM, van der Bom J, Rezende SM; Brazilian Immune Tolerance (BrazIT) Study group. Camelo RM, et al. Among authors: lorenzato cs. J Thromb Haemost. 2022 Nov;20(11):2526-2537. doi: 10.1111/jth.15878. Epub 2022 Sep 26. J Thromb Haemost. 2022. PMID: 36102352 Free article.
Multimodal molecular imaging of atherosclerosis: Nanoparticles functionalized with scFv fragments of an anti-αIIbβ3 antibody.
Larivière M, Lorenzato CS, Adumeau L, Bonnet S, Hémadou A, Jacobin-Valat MJ, Noubhani A, Santarelli X, Minder L, Di Primo C, Sanchez S, Mornet S, Laroche-Traineau J, Clofent-Sanchez G. Larivière M, et al. Among authors: lorenzato cs. Nanomedicine. 2019 Nov;22:102082. doi: 10.1016/j.nano.2019.102082. Epub 2019 Aug 9. Nanomedicine. 2019. PMID: 31404651
Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction.
Dias MM, Mesquita Camelo R, de Magalhães LP, Lemos Jardim L, Gonçalves de Oliveira A, Ribeiro RA, Karla Brognoli Franco V, Callado FMRA, Lorenzato CS, Rezende SM; Brazilian Immune Tolerance (BrazIT) Study group. Dias MM, et al. Among authors: lorenzato cs. Pediatr Hematol Oncol. 2024;41(1):74-80. doi: 10.1080/08880018.2023.2182853. Epub 2023 Feb 24. Pediatr Hematol Oncol. 2024. PMID: 36825651 No abstract available.
11 results